Evidence Review
Pilot Clinical Trial (Kumar et al., 2021)
This open-label pilot trial [1] enrolled eight older adults (average age 72) and eight young adults (average age 24) at Baylor College of Medicine. Older adults took GlyNAC for 24 weeks, then discontinued for 12 weeks. The trial measured glutathione concentrations, oxidative stress, mitochondrial function, inflammation, endothelial function, insulin resistance, genomic damage, muscle strength, and cognitive function at multiple timepoints.
At baseline, older adults had significantly lower glutathione, higher oxidative stress, impaired mitochondrial function, elevated inflammation, endothelial dysfunction, insulin resistance, greater genomic damage (DNA strand breaks), lower grip strength, and lower cognitive scores compared to young adults. After 24 weeks of GlyNAC, the older adults' glutathione levels rose and their oxidative stress markers fell toward young-adult levels. Mitochondrial fatty acid oxidation improved by 78%. All measured aging hallmarks improved significantly. After the 12-week washout, many benefits partially regressed, demonstrating that the effects were supplement-dependent. The trial authors noted that the scope of improvement — spanning so many independent aging mechanisms simultaneously — was unusual for a single intervention.
Randomized Controlled Trial (Kumar et al., 2023)
This double-blind RCT [2] enrolled 24 older adults and 12 young adults. Older adults were randomized to receive either GlyNAC or a placebo (alanine, a non-bioactive amino acid) for 16 weeks. Young adults received GlyNAC for 2 weeks. The trial pre-registered its hypotheses and used a rigorous placebo-controlled design, addressing a key limitation of the earlier pilot.
GlyNAC (but not placebo) corrected glutathione deficiency, reduced oxidative stress, improved mitochondrial dysfunction, reduced inflammation, improved insulin resistance, improved endothelial function, reduced body fat, decreased genomic toxicity, improved grip strength and gait speed, increased exercise capacity, and improved cognitive function. The placebo group showed no significant improvement in any of these measures. The effect sizes were large and clinically meaningful — for example, gait speed (a strong predictor of longevity) improved by 12% in the GlyNAC group versus no change in placebo. The authors described GlyNAC as correcting "a fundamental defect of aging" — the progressive inability to produce sufficient glutathione.
HIV Aging Study (Kumar et al., 2020)
This open-label trial [4] in people aging with HIV is notable because HIV patients on antiretroviral therapy experience accelerated aging — they develop many age-related conditions (cardiovascular disease, cognitive decline, metabolic dysfunction) earlier than the general population. This makes them a useful model for studying interventions targeting aging mechanisms.
Twenty-four weeks of GlyNAC in older HIV patients produced improvements across virtually the same spectrum of measures as the trials in the general aging population: glutathione improved, oxidative stress fell, mitochondrial function improved, inflammation decreased, insulin resistance improved, endothelial function improved, genomic damage decreased, and cognitive and physical function improved. This cross-disease consistency strengthens the case that GlyNAC is addressing a fundamental upstream process — glutathione depletion and its downstream consequences — rather than working through a disease-specific mechanism.
Mechanistic Review and Healthy Aging Implications (Sekhar, 2021)
This narrative review [3] by the principal investigator synthesized the theoretical and empirical case for GlyNAC in healthy aging. Sekhar reviewed evidence that glutathione deficiency in aging is not simply a consequence of increased oxidative stress but an upstream cause — driven by reduced synthesis of glycine and cysteine. The review highlighted that mitochondrial dysfunction and oxidative stress are interconnected: damaged mitochondria produce more reactive oxygen species, which deplete glutathione, which reduces the cell's ability to protect mitochondria, creating a self-amplifying cycle.
The review also presented a framework for why GlyNAC benefits such a wide range of outcomes. Rather than targeting one aging pathway, GlyNAC addresses a bottleneck that multiple pathways depend on. By restoring intracellular glutathione, GlyNAC simultaneously reduces the oxidative burden on mitochondria, lowers the inflammatory signaling triggered by oxidative stress, protects endothelial cells and DNA from oxidative damage, and supports the metabolic flexibility needed for proper glucose and fat handling. Sekhar argued that this breadth of effect is what distinguishes GlyNAC from more targeted antioxidant supplements.
Dose-Finding in Healthy Older Adults (Sekhar et al., 2022)
This randomized, placebo-controlled trial [5] investigated three different daily doses of GlyNAC in 114 healthy older adults over 2 weeks. The study was designed to establish dose-response relationships and confirm tolerability across a broader population before longer-term trials. All doses increased glutathione and reduced oxidative damage markers, with the highest dose showing the largest effect. The study provided reassurance that GlyNAC is safe and effective across a range of doses, supporting its use in diverse supplementation contexts.